Victoza® Product Monograph, Novo Nordisk Canada Inc.

November 17, 2017




(mL/min/1.73 m2)





No dosing adjustment required

*There is very limited or no clinical experience with Victoza® in patients with end-stage renal disease; use of Victoza® in these patients is not recommended.

Patients with renal insufficiency may experience more GI effects when treated with Victoza®. Use caution when initiating or escalating doses in patients with renal insufficiency. There have been post-marketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis in Victoza®-treated patients. Some of these events were reported in patients without known underlying renal disease.

Efficacy and Safety of Liraglutide vs Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.

Davies MJ et al. Diabetes Care. 2016;39(2):222-230.

A 26-week, double-blind, placebo-controlled, randomized, parallel-group trial.

As an add-on to insulin and/or OADs
In adults with type 2 diabetes and moderate renal insufficiency, Victoza® 1.8 mg at 26 weeks demonstrated:

Powerful mean A1C reductions vs. placebo4

Victoza® 1.8 mg (add-on to insulin and/or OADs)

Placebo (add-on to insulin and/or OADs):
-0.38%; p<0.0001 Victoza® 1.8 mg vs. placebo

Mean body weight reductions of -2.41 kg
(2° endpoint)4

Victoza® 1.8 mg (add-on to insulin and/or OADs)

Placebo (add-on to insulin and/or OADs):
-1.09 kg; p=0.0052 Victoza® 1.8 mg vs. placebo

A 26-week, double-blind, placebo-controlled, parallel-group trial randomized 279 patients with type 2 diabetes and moderate renal impairment (eGFR 30–59 mL/min/1.73 m2) to once-daily Victoza® 1.8 mg (n=140) or placebo (n=139) as add-on to insulin ± OADs. The primary outcome measure was change in A1C from baseline to week 26. Baseline values for Victoza® 1.8 mg (n=140) and placebo (n=137): A1C (%): 8.08 and 8.00, respectively; body weight (kg): 93.6 and 95.6, respectively.

§ Please see Product Monograph for complete dosing and administration information.

Victoza® is used in combination with MET, MET + SU, or with MET and a basal insulin. CrCL=Creatinine clearance; eGFR=Estimated glomerular filtration rate; GI=Gastrointestinal; OAD=Oral antihyperglycemic drug.

Ask Med Info

If you have a specific question about Victoza®, please email our Medical Information team using the form below. We will get back to you as soon as possible.


The latest Victoza® Product Monograph dated November 17, 20171.

The new Victoza® VIP program is a resource for you to use with your patients during consultations, including how-to videos and other resources to get them started.

TRUST in our real-world experience.

#1 GLP-1 receptor agonist dispensed, Canada and worldwide2,3

>1,120,000 patients worldwide have been prescribed Victoza® 3